* Allelix Biopharmaceuticals Inc., of Toronto, said Canadianscientists published the discovery and function of the peptide-hormone GLP-2 (glucagon-like peptide-2) in the Proceedings of theNational Academy of Sciences. The peptide-hormone stimulates thegrowth of the lining of the small intestine, vital to digesting food.Allelix is developing GLP-2 as a treatment for intestinal diseases.
* Neurex Corp., of Menlo Park, Calif., said a paper presented at anischemia conference showed four patients who received SNX-111after head trauma had good to excellent outcomes when dischargedfrom the hospital. Phase II studies are continuing and the companyhopes to begin pivotal studies early in 1997.
* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said the FDAapproved an increase of shelf life time for Doxil, or liposomaldoxorubicin, from 14 to 20 months. The product is approved fortreatment of Kaposi's sarcoma.
(c) 1997 American Health Consultants. All rights reserved.